CAJ | 학술논문

背景:生物反应调节剂己成为继化疗、手术及放疗后第4种治疗肿瘤的方法.云芝糖肽是一种生物反应调节剂物质,在肿瘤治疗中具有重要作用,己被应用于胃癌、肺癌、食道癌等的治疗.目的:观察云芝糖肽对因妇科恶性肿瘤而化疗的患者免疫功能与生活质量的影响.设计:对比观察.单位:上海交通大学附属第一人民医院妇产科.对象:选择1999-06/2002-12上海交通大学附属第一人民医院妇产科已手术确诊的妇科恶性肿瘤住院患者共40例.其中卵巢癌36例,平均年龄52岁;子宫体癌4例,平均年龄54岁.纳入标准:卵巢或子宫体癌患者,手术后没有化疗禁忌征.排除标准:有化疗禁忌征的患者.方法:将患者按期别及年龄配对分成试验组和对照组,每组20例.试验组接受化疗加云芝糖肽;对照组单用化疗.卵巢癌采用PAC方案化疗,子宫体癌用MFP方案.实验时机于第2次化疗开始前至第4次化疗前,共2个月.主要观察指标:各组治疗前后血免疫功能指标及生活质量指数的变化.结果:纳入患者40例,均进入结果分析.①治疗前后Karnofsky评分值试验组分别为(84±9.6),(90±8.6)分,(P＜0.05);对照组分别为(83±9.2)及(80±12.8)分,(P＞0.05);治疗后试验组比对照组高10分,(P＜0.05).②治疗后试验组和对照组的CD4+分别为28.14±4.10及23.12±3.97,(P＜0.05);CD4+/CD8+为0.96±0.17及0.75±0.21,(P＜0.01);自然杀伤细胞为23.80±4.90,5.32±3.90,(P＜0.01),试验组均明显高于对照组.结论:云芝糖肽能提高卵巢和子宫体癌患者的细胞免疫和生活质量.
배경:생물반응조절제기성위계화료、수술급방료후제4충치료종류적방법.운지당태시일충생물반응조절제물질,재종류치료중구유중요작용,기피응용우위암、폐암、식도암등적치료.목적:관찰운지당태대인부과악성종류이화료적환자면역공능여생활질량적영향.설계:대비관찰.단위:상해교통대학부속제일인민의원부산과.대상:선택1999-06/2002-12상해교통대학부속제일인민의원부산과이수술학진적부과악성종류주원환자공40례.기중란소암36례,평균년령52세;자궁체암4례,평균년령54세.납입표준:란소혹자궁체암환자,수술후몰유화료금기정.배제표준:유화료금기정적환자.방법:장환자안기별급년령배대분성시험조화대조조,매조20례.시험조접수화료가운지당태;대조조단용화료.란소암채용PAC방안화료,자궁체암용MFP방안.실험시궤우제2차화료개시전지제4차화료전,공2개월.주요관찰지표:각조치료전후혈면역공능지표급생활질량지수적변화.결과:납입환자40례,균진입결과분석.①치료전후Karnofsky평분치시험조분별위(84±9.6),(90±8.6)분,(P＜0.05);대조조분별위(83±9.2)급(80±12.8)분,(P＞0.05);치료후시험조비대조조고10분,(P＜0.05).②치료후시험조화대조조적CD4+분별위28.14±4.10급23.12±3.97,(P＜0.05);CD4+/CD8+위0.96±0.17급0.75±0.21,(P＜0.01);자연살상세포위23.80±4.90,5.32±3.90,(P＜0.01),시험조균명현고우대조조.결론:운지당태능제고란소화자궁체암환자적세포면역화생활질량.
BACKGROUND: The application of biological response modifiers (BRMs) has become the fourth cancer treatment following surgery, chemotherapy and radiotherapy. Polysaccharide-peptide (PSP) is a biological response modifier substance playing a special role in cancer treatment, which has been used in the treatment of gastric cancer, lung cancer, esophagual can cer, etc. With good results. OBJECTIVE: To observe the effect of PSP on the immune function and quality of life (QOL) in patients receiving chemotherapy for gynecological malignancies. DESIGN: A comparative observation. SETTING: Department of Obstetrics and Gynecology, Shanghai Jiaotong University Affiliated First People's Hospital. PARTICIPANTS: Forty patients who had been operated on for gyneco logical malignancies were selected from the Department of Obstetrics and Gynecology, Shanghai Jiaotong University Affiliated First People's Hospital from June 1999 to December 2002, including 36 cases of ovarian cancer with an average age of 52 years and 4 cases of endometrial cancer with an average age of 54 years. Patients with ovarian or endometrial cancer suffered from no contraindication in chemotherapy postoperatively were enrolled, otherwise were excluded.METHODS: The 40 patients were divided into study group (n=20) and control group (n=20) by matching according to stage and age. In the study group, the patients were treated with PSP capsules in addition to chemotherapy, whereas those in the control group were treated with chemotherapy only. PAC (phenacetin, spirin, caffeine) and MFP (melphalan, 5-fluorouracil, medroxyprogesterone acetate) regimens were adopted for the ovarian cancers and endometrial cancer respectively. The experiment lasted for two months from the beginning of the second course of chemotherapy to the beginning of the fourth one.MAIN OUTCOME MEASURES: The indexes of blood immune function and QOL were observed before and after treatment.RESULTS: All the 40 patients were involved in the analysis of results. ①The average Karnofkky's scores before and after treatment were (84±9.6)and (90±8.6) in the study group (P ＜ 0.05), and (83±9.2), (80±12.8) in the control group (P ＞ 0.05). The average Karnofkky's score was 10 credits higher in the study group than in the control group (P ＜ 0.05). ② The CD4+,CD4+/CD8+ and natural killer cells after treatment in the study group were all obviously higher than those in the control group (28.14±4.10, 0.96±0.17,23.80±4.90; 23.12±3.97, 0.75±0.21, 5.32±3.90) (P ＜ 0.05, 0.01).CONCLUSION: PSP can improve the cellular immunity and QOL of patients with ovarian or endometrial cancers.